Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Zogenix, Inc.’s (ZGNX - Snapshot Report) fourth-quarter 2012 adjusted net loss of 16 cents per share was narrower than the year-ago loss of 36 cents per share and the Zacks Consensus Estimate of a loss of 17 cents per share. The narrower loss was primarily attributable to lower selling, general and administrative (SG&A) expenses incurred by Zogenix in the final quarter of 2012.

Quarterly Highlights

Total revenues in the reported quarter climbed 20.2% to $9.5 million. Revenues marginally missed the Zacks Consensus Estimate of $10 million. Entire revenues in the final quarter of 2012 came from net product sales.

Revenues in the year-ago quarter included contract revenue worth $2.5 million pertaining to Zogenix‘s co-promotion agreement with Astellas Pharma (ALPMY). The deal, which was regarding Zogenix’s injectable migraine and cluster headache therapy Sumavel DosePro, was terminated on Mar 31, 2012.

Research and development (R&D) expenses came in at $5.4 million, flat year over year. SG&A expenses declined 33.1% to $11.9 million. The decline was primarily attributable to the $5.7 million reduction in service fees to Astellas Pharma following the termination of Zogenix’s co-promotion agreement with the latter.

Annual Results

For full year 2012, Zogenix suffered a loss of 72 cents per share, compared with the year-ago loss of $1.97 per share. The Zacks Consensus Estimate for 2012 hinted at a loss of 79 cents per share. Total revenues climbed 17.8% to $44.3 million, short of the Zacks Consensus Estimate of $45 million.

Zogenix carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the pharma sector include Lannett Company, Inc. (LCI - Snapshot Report) and WuXi PharmaTech (Cayman) Inc. (WX - Snapshot Report). Both the stocks carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RAMBUS INC RMBS 12.43 +5.43%
BOFL HOLDING BOFI 84.98 +4.58%
DIXIE GROUP DXYN 15.23 +3.75%
DAIMLER AG DDAIF 92.96 +2.88%